// App-Quantinova.ai

: ETCTN 10476: A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer.

Researchers

Presenter

  • Thatcher Ross Heumann

Principal Investigators

  • Mark Yarchoan

  • Judy Murray

  • Hao Wang

  • John Joseph Wright

  • Elad Sharon

  • Gregory B. Lesinski

  • Nilofer Saba Azad

Medical Centers

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

  • Cancer Therapy Evaluation Program, Division of Cancer Treatment & Diagnosis, National Cancer Institute of the National Institutes of Health, Bethesda, MD

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

Biomarkers

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

  • Fibroblast Growth Factor Receptor 2

  • Isocitrate dehydrogenase 1

Drug/Treatment

  • Atezolizumab

  • Cobimetinib

  • Durvalumab

  • Varlilumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • II

Study Id's

  • NCT03201458

  • NCT04941287

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved